Stable and highly concentrated formulation of the antibody nimotuzumab

The present invention relates to the fields of biotechnology and medicine and describes high-concentration pharmaceutical formulations comprising the humanised monoclonal antibody nimotuzumab in a concentration range between 50 and 200 mg/mL. The low viscosity values of these solutions enable them t...

Full description

Saved in:
Bibliographic Details
Main Authors FERNÁNDEZ SÁEZ, Olga Lidea, HERNÁNDEZ TERRERO, Yaiko Saddan, CASTILLO VITLOCH, Adolfo, CEDEÑO ARIAS, Mercedes, BOGGIANO AYO, Tammy, LEÓN MONZÓN, Kalet, RASHIDA DE LA LUZ HERNÁNDEZ, Kathya, SANTO TOMÁS POMPA, Julio Felipe
Format Patent
LanguageEnglish
Published 08.08.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the fields of biotechnology and medicine and describes high-concentration pharmaceutical formulations comprising the humanised monoclonal antibody nimotuzumab in a concentration range between 50 and 200 mg/mL. The low viscosity values of these solutions enable them to be used subcutaneously or intramuscularly in cancer treatments. These formulations are stable in both liquid and freeze-dried forms.
Bibliography:Application Number: AU20200409887